

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Declaration for Patent Application

As a named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated next to my name;

I believe I am the original, first and sole inventor (if only one name is listed) or an original, first and joint inventor (if plural names are listed in the signatory page(s) commencing at page 3 hereof) of the subject matter which is claimed and for which a patent is sought on the invention entitled

ANTI-TNF ANTIBODIES AND METHOTREXATE

IN THE TREATMENT OF AUTOIMMUNE DISEASE

the specification of which (check one)

☐ is attached hereto.

☒ was filed on August 1, 1996 as United States Application

Serial No. 08/690,775.

and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is known by me to be material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

Priority
Not
Claimed
[]

(Number) (Country) (Day/Month/Year filed)

[]

(Number) (Country) (Day/Month/Year filed)

[]

(Number) (Country) (Day/Month/Year filed)

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

(Application Number) (Filing Date)

(Application Number) (Filing Date)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States

application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information known by me to be material to patentability as defined in 37 C.F.R. §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

<u>08/607,419</u> (Application Serial No.)	<u>February 28, 1996</u> (Filing date)	<u>pending</u> (Status, patented, pending, abandoned)
<u>PCT/GB94/00462</u> (Application Serial No.)	<u>March 10, 1994</u> (Filing date)	<u>pending</u> (Status, patented, pending, abandoned)
<u>PCT/GB93/02070</u> (Application Serial No.)	<u>October 6, 1993</u> (Filing date)	<u>pending</u> (Status, patented, pending, abandoned)
<u>07/958,248</u> (Application Serial No.)	<u>October 8, 1992</u> (Filing date)	<u>abandoned</u> (Status, patented, pending, abandoned)

As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

I also hereby grant additional Powers of Attorney to the following attorneys and/or agents to file and prosecute an international application under the Patent Cooperation Treaty based upon the above-identified application, including a power to meet all designated office requirements for designated states:

David E. Brook	Reg. No. 22,592	Thomas O. Hoover	Reg. No. 32,470
James M. Smith	Reg. No. 28,043	Alice O. Carroll	Reg. No. 33,542
Leo R. Reynolds	Reg. No. 20,884	N. Scott Pierce	Reg. No. 34,900
Patricia Granahan	Reg. No. 32,227	Richard A. Wise	Reg. No. 18,041
Mary Lou Wakimura	Reg. No. 31,804	Carolyn S. Elmore	Reg. No. 37,567
		Helen Lee	Reg. No. 39,270

All of Hamilton, Brook, Smith and Reynolds, P.C., Two Militia Drive, Lexington, Massachusetts 02173.

Send correspondence to: David E. Brook, Esq., Hamilton, Brook, Smith & REYNOLDS, Two Militia Drive, Lexington, Massachusetts 02173-4799

Direct telephone calls to: David E. Brook, Esq.

(617) 861-6240

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole

or first inventor Marc Feldmann

Inventor's

Signature 

Date 20 Sept 96

Residence

2 Church Road

Highgate, London N6 4QT, ENGLAND

Citizenship

Australia

Post Office Address

Same as above

Full name of second joint

inventor, if any Ravinder N. Maini

Second Inventor's

Signature RNM Date 23/9/86

Residence 151 Castelnau

Barnes, London SW13 9EW, ENGLAND
Citizenship United Kingdom

Post Office Address Same as above

Full name of third joint

inventor, if any _____

Third Inventor's

Signature _____ Date _____

Residence _____

Citizenship _____

Post Office Address _____

Full name of fourth joint

inventor, if any _____

Fourth Inventor's

Signature _____ Date _____

Residence _____

Citizenship _____

Post Office Address _____

Full name of fifth joint

inventor, if any _____

Fifth Inventor's

Signature _____ Date _____

Residence _____

Citizenship _____

Post Office Address _____

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Marc Feldmann and Ravinder N. Maini

Application No.: 08/690,775 Group Art Unit: 1644

Filed: August 1, 1996 Examiner: P. Gambel

Title: ANTI-TNF ANTIBODIES AND METHOTREXATE IN THE TREATMENT
OF AUTOIMMUNE DISEASE

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231	
on <u>4/23/01</u>	<u>Sandra Jammal</u>
Date	Signature
<u>Sandra Jammal</u>	
Typed or printed name of person signing certificate	

REVOCATION OF POWERS OF ATTORNEY
AND APPOINTMENT OF NEW ATTORNEYS AND/OR AGENTS

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The Kennedy Institute of Rheumatology, a Corporation duly organized under the laws of the United Kingdom, is the assignee of the entire right, title and interest in the above-identified application. The Kennedy Institute of Rheumatology hereby appoints:

John P. White, Esq.
Registration No.: 28,678
Cooper & Dunham
1185 Avenue of the Americas
New York, New York 10036

to prosecute the above-identified application and any divisions or continuations thereof and to conduct all business in the United States Patent and Trademark Office. All previously granted Powers of Attorney are hereby revoked.

Certification under 37 C.F.R. §3.73(b) is submitted herewith.

Respectfully submitted,

By R. N. Mani

Homework

Ravinder N. Maini
Honoring *DNM*
Title: / Director, and Trustee
The Kennedy Institute of Rheumatology

Date 18/4/2001

Case	Age	Sex	Site	Pathologic	Survival
1	65	M	Rectum	Adenocarcinoma	10 mo
2	68	M	Rectum	Adenocarcinoma	12 mo
3	70	M	Rectum	Adenocarcinoma	14 mo
4	72	M	Rectum	Adenocarcinoma	16 mo
5	74	M	Rectum	Adenocarcinoma	18 mo
6	76	M	Rectum	Adenocarcinoma	20 mo
7	78	M	Rectum	Adenocarcinoma	22 mo
8	80	M	Rectum	Adenocarcinoma	24 mo
9	82	M	Rectum	Adenocarcinoma	26 mo
10	84	M	Rectum	Adenocarcinoma	28 mo
11	86	M	Rectum	Adenocarcinoma	30 mo
12	88	M	Rectum	Adenocarcinoma	32 mo
13	90	M	Rectum	Adenocarcinoma	34 mo
14	92	M	Rectum	Adenocarcinoma	36 mo
15	94	M	Rectum	Adenocarcinoma	38 mo
16	96	M	Rectum	Adenocarcinoma	40 mo
17	98	M	Rectum	Adenocarcinoma	42 mo
18	100	M	Rectum	Adenocarcinoma	44 mo
19	102	M	Rectum	Adenocarcinoma	46 mo
20	104	M	Rectum	Adenocarcinoma	48 mo
21	106	M	Rectum	Adenocarcinoma	50 mo
22	108	M	Rectum	Adenocarcinoma	52 mo
23	110	M	Rectum	Adenocarcinoma	54 mo
24	112	M	Rectum	Adenocarcinoma	56 mo
25	114	M	Rectum	Adenocarcinoma	58 mo
26	116	M	Rectum	Adenocarcinoma	60 mo
27	118	M	Rectum	Adenocarcinoma	62 mo
28	120	M	Rectum	Adenocarcinoma	64 mo
29	122	M	Rectum	Adenocarcinoma	66 mo
30	124	M	Rectum	Adenocarcinoma	68 mo
31	126	M	Rectum	Adenocarcinoma	70 mo
32	128	M	Rectum	Adenocarcinoma	72 mo
33	130	M	Rectum	Adenocarcinoma	74 mo
34	132	M	Rectum	Adenocarcinoma	76 mo
35	134	M	Rectum	Adenocarcinoma	78 mo
36	136	M	Rectum	Adenocarcinoma	80 mo
37	138	M	Rectum	Adenocarcinoma	82 mo
38	140	M	Rectum	Adenocarcinoma	84 mo
39	142	M	Rectum	Adenocarcinoma	86 mo
40	144	M	Rectum	Adenocarcinoma	88 mo
41	146	M	Rectum	Adenocarcinoma	90 mo
42	148	M	Rectum	Adenocarcinoma	92 mo
43	150	M	Rectum	Adenocarcinoma	94 mo
44	152	M	Rectum	Adenocarcinoma	96 mo
45	154	M	Rectum	Adenocarcinoma	98 mo
46	156	M	Rectum	Adenocarcinoma	100 mo
47	158	M	Rectum	Adenocarcinoma	102 mo
48	160	M	Rectum	Adenocarcinoma	104 mo
49	162	M	Rectum	Adenocarcinoma	106 mo
50	164	M	Rectum	Adenocarcinoma	108 mo
51	166	M	Rectum	Adenocarcinoma	110 mo
52	168	M	Rectum	Adenocarcinoma	112 mo
53	170	M	Rectum	Adenocarcinoma	114 mo
54	172	M	Rectum	Adenocarcinoma	116 mo
55	174	M	Rectum	Adenocarcinoma	118 mo
56	176	M	Rectum	Adenocarcinoma	120 mo
57	178	M	Rectum	Adenocarcinoma	122 mo
58	180	M	Rectum	Adenocarcinoma	124 mo
59	182	M	Rectum	Adenocarcinoma	126 mo
60	184	M	Rectum	Adenocarcinoma	128 mo
61	186	M	Rectum	Adenocarcinoma	130 mo
62	188	M	Rectum	Adenocarcinoma	132 mo
63	190	M	Rectum	Adenocarcinoma	134 mo
64	192	M	Rectum	Adenocarcinoma	136 mo
65	194	M	Rectum	Adenocarcinoma	138 mo
66	196	M	Rectum	Adenocarcinoma	140 mo
67	198	M	Rectum	Adenocarcinoma	142 mo
68	200	M	Rectum	Adenocarcinoma	144 mo
69	202				

CERTIFICATE UNDER 37 C.F.R. § 3.73(b)Applicants: Marc Feldmann and Ravinder N. MainiApplication No.: 08/690,775 Filed: August 1, 1996For: ANTI-TNF ANTIBODIES AND METHOTREXATE IN THE TREATMENT OF AUTOIMMUNE DISEASEThe Kennedy Institute of Rheumatology, a Corporation,
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

certifies that it is

- A. ☒ the assignee of the entire right, title and interest in the patent application identified above.
- B. ☐ an assignee together with ☐ of the entire right, title and interest in the patent application identified above. A separate Certificate under 37 CFR § 3.73(b) is attached.

The right, title and interest of the above-named assignee in the patent application identified above is established by virtue of:

- A. ☒ An assignment from the inventors of the patent application identified above. The assignment was recorded in the Patent and Trademark Office at Reel 8168, Frame 0822-0824, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s) of the patent application identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are attached.☐ Copies of assignments or other documents in the chain of title are attached.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: 15/4/2001Name: Ravinder N. MainiTitle: Director, The Kennedy Institute of RheumatologySignature: Ravinder N. Maini